Processes Patents (Class 536/55.3)
  • Patent number: 11079374
    Abstract: Disclosed herein are methods and kits for isolating exosomes in a sample. The method comprises contacting and incubating a plurality of galectin-3-modified magnetic beads with the sample, followed by subjecting the mixture to a magnetic field and then isolating the exosomes from the magnetic beads by a lactose solution. The kit of the present disclosure comprises a plurality galectin-3-modified magnetic beads, a lactose solution having a pH value of 6.8 to 7.6, and an exosome-free buffer.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 3, 2021
    Assignees: BIOVESICLE INC
    Inventors: Dapi Meng Lin Chiang, Michael W. Pfaffl, Dominik Buschmann
  • Patent number: 10684285
    Abstract: The present disclosure relates to methods and a kit for diagnosing, prognosing and/or monitoring a gynaecological disease, especially epithelial ovarian cancer, on the basis of altered glycosylation pattern of CA125. More specifically, said altered glycosylation pattern relates to that recognizable by MGL.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: June 16, 2020
    Assignee: KAIVOGEN OY
    Inventors: Kim Pettersson, Kamlesh Gidwani
  • Patent number: 10233260
    Abstract: A functionalization is performed with a dissolved oligo- or polysaccharide derivative which contains at least one free functional group, especially an amino group, linked through a polar carbamate linkage and a spacer (X), according to the general formula I:
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: March 19, 2019
    Assignee: FZMB GMBH Forschungszentrum Fuer Medizintechnik Und Biotechnologie
    Inventors: Thomas Heinze, Holger Wondraczek, Thomas Elschner, Friedrich Scholz
  • Patent number: 9834515
    Abstract: The present invention discloses a process for synthesis of piperidine alkaloids selected from fagomine, 4-epi-fagomine and nojirimycin from tri-O-benzyl-D-glucal or tri-O-benzyl-D-galactal.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: December 5, 2017
    Assignee: Council of Scientific and Industrial Research
    Inventors: Asish Kumar Bhattacharya, Hemender Rami Chand
  • Patent number: 9089156
    Abstract: Edible compositions, such as sports drinks which limit muscle soreness, and methods of making and using the same are provided. Existing food products are commonly used during exercise to quickly replace fluids and electrolytes lost by sweating and/or to supply a boost of carbohydrates to improve sports or exercise performance. Aspects of the invention relate to compositions including glucosamine to alleviate or prevent muscle soreness. In certain embodiments, the glucosamine may be derived from a plurality of glucosamine sources. Further aspects relate to concentrated products for preparing beverage compositions. In certain embodiments, a concentrated form of a beverage composition may be provided in a packaging. Instructions for preparing the beverage composition having an effective amount of glucosamine may also be provided. Further embodiments may include a notification that indicates the benefit of reducing or preventing muscle soreness following physical exertion by consuming the beverage formulation.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: July 28, 2015
    Assignee: Stokely-Van Camp, Inc.
    Inventors: Vincent Rinaldi, William Racicot, Jeffrey J. Zachwieja, Robert Murray
  • Patent number: 9040681
    Abstract: A production method of a cationized cellulose or a cationized hydroxyalkylcellulose, including step 1 for adding a cationizing agent to cellulose and mechanically decrystallizing the cellulose and step 2 for adding a basic compound to the mixture obtained in step 1 and mechanically decrystallizing the cellulose, or a production method of a cationized cellulose or a cationized hydroxyalkylcellulose, including a step 3 for adding a basic compound to cellulose and mechanically decrystallizing the cellulose and step 4 for adding a cationizing agent to the mixture obtained in step 3 and mechanically decrystallizing the cellulose. The cellulose and the cationizing agent are allowed to react with each other in step 2 or step 4.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: May 26, 2015
    Assignee: KAO CORPORATION
    Inventors: Akiyoshi Kimura, Keiichiro Tomioka, Toru Nishioka, Kohei Nakanishi
  • Publication number: 20150073134
    Abstract: The present invention is a multilayered composite comprising porous metal oxide particles that are covalently bonded by way of inorganic ether groups to one or more sites of a first polyhydroxyl-functionalized polymer. This first polymer is in turn covalently bonded by way of inorganic ether groups to one or more sites of a second polyhydroxyl-functionalized polymer. The multilayered composites can be prepared by contacting porous inorganic-oxide particles with a sufficient amount of OH-reactive crosslinking agent to form metal oxide particles imbibed with the crosslinking agent, and then contacting the inorganic-oxide particles with a solution of polyhydroxyl-functionalized polymer under reactive conditions.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 12, 2015
    Applicants: The Regents of the University of California, Rohm and Haas Company, Dow Global Technologies LLC
    Inventors: Joseph Jankolovits, Alexander S. Katz, Oz M. Gazit, James C. Bohling, John A. Roper, III
  • Patent number: 8962821
    Abstract: The present invention relates to a non-toxic process and system for pilot-scale production of cellulose products, and particularly to a process and system for pilot-scale production of cellulose products by using aqueous sodium hydroxide/urea solution pre-colled to lower than ?8° C., in which cellulose could dissolved rapidly. The said process and system can be used to produce fibers, films, chromatographic packings, or nonwovens of regenerated cellulose, as well as to produce a variety of high added-value products by adding other materials such as functional materials, nano-materials, etc.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: February 24, 2015
    Assignees: Jiangsu Long-Ma Green Fibers Co., Ltd., Wuhan University
    Inventors: Lina Zhang, Jie Cai, Jinping Zhou, Chuntao Li, Haisong Qi, Yuan Mao
  • Patent number: 8940888
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: January 27, 2015
    Assignee: Prochon Biotech Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Publication number: 20150011747
    Abstract: Sugar-acrylic monomers are synthesized to have a carbohydrate moiety linked to an acrylate group. The sugar-acrylic monomers may be polymerized to form polymers, adhesives, hydrogels, and the like. The sugar-acrylic monomers and polymers may be used in tissue engineering, adhesives and sealers, wound healing, and the like.
    Type: Application
    Filed: September 26, 2014
    Publication date: January 8, 2015
    Applicant: Empire Technology Development LLC
    Inventors: William B. Carlson, Gregory D. Phelan, Phillip A. Sullivan
  • Publication number: 20140336369
    Abstract: Processes are disclosed for the synthesis of the Factor Xa anticoagulant fondaparinux and related compounds. Protected pentasaccharide intermediates and efficient and scalable processes for the industrial scale production of fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions are provided.
    Type: Application
    Filed: July 23, 2014
    Publication date: November 13, 2014
    Applicant: APICORE US LLC
    Inventors: Ravishanker Kovi, Ashish Naik, Brijesh Patel, Muralikrishna Madala
  • Publication number: 20140329998
    Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.
    Type: Application
    Filed: September 14, 2012
    Publication date: November 6, 2014
    Applicant: NOVARTIS AG
    Inventors: Allan James Saul, Francesca Micoli
  • Publication number: 20140316128
    Abstract: Described are oligo- and polysaccharides containing amine groups. Specifically, described is a new process to manufacture cationic cellulose oligomers. The new cationic oligo- or polysaccharides are useful ingredients in various aqueous compositions, inter alia as ingredients for personal care compositions.
    Type: Application
    Filed: October 4, 2012
    Publication date: October 23, 2014
    Inventors: Mari Granström, Volker Wendel, Anja Suckert, Claudia Wood, Helmuth Völlmar, Anni Knab, Alois Kindler, Marta Zajaczkowski-Fischer
  • Publication number: 20140314671
    Abstract: Embodiments of the present disclosure provide for labeled probes such as labeled maltose probes and labeled acarbose probes, methods of making labeled probes, pharmaceutical compositions including labeled probes, methods of using labeled probes, methods of diagnosing, localizing, monitoring, and/or assessing bacterial infections, using labeled probes, kits for diagnosing, localizing, monitoring, and/or assessing bacterial infections, using labeled probes, and the like.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 23, 2014
    Inventors: Mohammad Namavari, Gayatri Gowrishankar, Sanjiv S. Gambhir
  • Publication number: 20140287471
    Abstract: The present disclosure relates to variant CBH I polypeptides that have reduced product inhibition, and compositions, e.g., cellulase compositions, comprising variant CBH I polypeptides. The variant CBH I polypeptides and related compositions can be used in variety of agricultural and industrial applications. The present disclosure further relates to nucleic acids encoding variant CBH I polypeptides and host cells that recombinantly express the variant CBH I polypeptides.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 25, 2014
    Applicant: Bp Corporation North America Inc.
    Inventors: Sarah Richardson Hanson, Justin T. Stege, Cecilia Cheng, Peter Luginbuhl
  • Publication number: 20140275291
    Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: HemCon Medical Technologies, Inc.
    Inventors: Barbara McGrath, Simon McCarthy, Sam Kuhn, Alysha Wold, Michael Stolten, Amanda Bennett
  • Patent number: 8829181
    Abstract: The present invention relates to a process for producing a cationic hydroxypropyl cellulose including the step of reacting a low-crystalline powdery cellulose with a cationizing agent represented by the following general formula (1) and/or a cationizing agent represented by the following general formula (2), and propylene oxide in the presence of water in an amount of from 10 to 60% by mass on the basis of the low-crystalline powdery cellulose, and a catalyst: wherein R1 to R3 are each independently a linear or branched hydrocarbon group having 1 to 4 carbon atoms; and X and Z are each a halogen atom and may be the same or different from each other.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: September 9, 2014
    Assignee: KAO Corporation
    Inventors: Masanori Takai, Masafumi Miyamoto, Kohei Nakanishi, Toru Nishioka
  • Patent number: 8828732
    Abstract: The method of labeling a sugar chain from a biological sample employs a single reaction vessel for the sequential performance of the following steps of (a) isolating a sugar chain from a sample using a sugar-trapping substance; (b) washing the sugar-trapping substance having the sugar chains trapped thereon; (c) releasing the sugar chain from the sugar-trapping substance; and (d) labeling the released sugar chain with UV/visible or fluorescent compound having an amino group forming a stable labeled sugar in fewer steps than a conventional ion exchange based technique.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: September 9, 2014
    Assignee: Sumitomo Bakelite Co., Ltd.
    Inventors: Midori Abe, Hideyuki Shimaoka, Hiromitsu Kuramoto
  • Patent number: 8822674
    Abstract: A highly stable crystal of (1S)-1,5-anhydro-1-[5-(4-{(1E)-4-[(1-{[2-(dimethylamino)ethyl]amino}-2-methyl-1-oxopropan-2-yl)amino]-3,3-dimethyl-4-oxobut-1-en-1-yl}benzyl)-2-methoxy-4-(propan-2-yl)phenyl]-D-glucitol, and a process for producing the crystal are provided. Specifically, an ethanolate having the following physical properties, and a plurality of other crystal forms transformed from the ethanolate are provided: (a) Having peaks at 2?=5.9 degrees, 17.1 degrees, 17.6 degrees and 21.5 degrees in X-ray powder diffraction (Cu—K?); (b) Showing characteristic absorption bands at 3538 cm?1, 3357 cm?1, 2964 cm?1, 1673 cm?1, 1634 cm?1 and 1505 cm?1 in an infrared absorption spectrum; and (c) Having a melting point in a vicinity of 111° C.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: September 2, 2014
    Assignee: Taisho Pharmaceutical Co., Ltd
    Inventors: Yoshihiro Kimura, Koreaki Imura, Naoto Osaki, Ayumi Matsushima
  • Patent number: 8822659
    Abstract: Procedure for the synthesis of deprotected pentasaccharides from a protected precursor pentasaccharide through a reaction procedure having five stages whereamong is included an N-sulphation of amino groups and a hydrogenolysis of benzyl groups. Through this procedure a drastic reduction is achieved in the total synthesis time in comparison with the process traditionally employed, together with increased reproducibility thereof, permitting the standardization thereof.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: September 2, 2014
    Assignee: Laboratorios Farmacéutios Rovi, S.A.
    Inventors: Ivan Lopez-Belmonte Encina, Rafael Ojeda Martinez De Castilla
  • Publication number: 20140243283
    Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.
    Type: Application
    Filed: December 18, 2013
    Publication date: August 28, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Yeeman K. Ramtohul, Sanjoy Kumar Das, Caroline Cadilhac, Thumkunta Jagadeeswar Reddy, Louis Vaillancourt, Michel Gallant, Bingcan Liu, Evelyne Dietrich, Frederic Vallee, Julien Martel, Carl Poisson
  • Patent number: 8802841
    Abstract: A 1,2-dideoxy-1,2-diamino oligosaccharide or polysaccharide in its free base, salt or metal-complex form as shown in General Formula 1 and derivative thereof is described. R1, R2 and R3 are each independently selected from the group consisting of H and a carbohydrate moiety, with the proviso that at least one of the groups R1, R2 or R3 is a carbohydrate moiety; R4 is selected from the group consisting of: H, optionally substituted C1-20-alkyl, optionally substituted heteroalkyl, optionally substituted C2-20-alkenyl, optionally substituted C2-20-alkynyl, optionally substituted C3-10-cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: August 12, 2014
    Assignee: Glycom A/S
    Inventors: Gyula Dekany, István Bajza, Marie Bøjstrup, Károly Ágoston, Lars Kröger, Ignacio Figueroa Pérez, Christoph H. Röhrig, Paulo Vital, Erzsébet Czinege
  • Patent number: 8742094
    Abstract: The invention relates to a method for producing phosphate-bridged nucleoside conjugates. In the method, a cyclosaligenyl nucleotide is produced first, to which a linker is added, which is used to perform the immobilization on a solid phase. A subsequent reaction with corresponding nucleophiles results in the desired phosphate-bridged nucleoside conjugates, which can then again be cleaved from the solid phase-bound linker.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: June 3, 2014
    Assignee: Universitaet Hamburg
    Inventors: Chris Meier, Viktoria Caroline Tonn
  • Patent number: 8735571
    Abstract: A composition of exceptionally dense chitosan and a novel method for producing the dense chitosan structure have been described. The novel production method employs coincident compression and vacuum on a neutralized chitosan polymer that results in an exceptionally dense chitosan film or membrane material. The dense chitosan film or membrane composition possesses multiple physical and clinically appealing qualities for a variety of medical applications on or in animals, mammals, or humans.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: May 27, 2014
    Assignee: Agenta Biotechnologies, Inc.
    Inventors: Arthur A. DeCarlo, April Ellis, Thomas P. Dooley, Maria Belousova
  • Patent number: 8729185
    Abstract: Provided is a method for producing a 2-cyanoethyl group-containing organic compound having a high ratio of replacement by cyanoethyl groups and a high dielectric constant. More specifically, provided is a method for producing a 2-cyanoethyl group-containing organic compound comprising a step of reacting acrylonitrile with a hydroxyl group-containing organic compound in the presence of a quaternary ammonium salt as a catalyst through a Michael addition.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: May 20, 2014
    Assignees: Shin-Etsu Chemical Co., Ltd., Matsugaki Chemical Industries Co., Ltd.
    Inventors: Ikuo Fukui, Kazuhisa Hayakawa, Soji Tanioka, Masahiro Ohgata, Masaaki Kajitani
  • Patent number: 8703923
    Abstract: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 22, 2014
    Assignee: Reliable Biopharmaceutical Corporation
    Inventors: Sourena Nadji, James T. Smoot, Joseph A. Vanartsdalen
  • Patent number: 8691973
    Abstract: Provided are a method of producing a porous chitosan scaffold, the method including: providing an aqueous acidic solution having chitosan and a solvent which does not dissolve the chitosan; and freeze-drying the aqueous acidic solution, wherein the solvent is selected from the group consisting of a C3-C8 aliphatic alcohol having one hydroxy group, ethylene glycol monoethylether, ethylene glycol monobutylether, dioxane, tetrahydrofuran, dimethylcarbonate, acetone and acetonitrile, and a chitosan scaffold produced using the method.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: April 8, 2014
    Assignee: Korea Institute of Radiological & Medical Sciences
    Inventors: Chun-Ho Kim, Seung-Jae Lee, Jin-Ik Lim, Youngsook Son
  • Patent number: 8691957
    Abstract: The present invention is provides a crosslinked hyaluronan powder excellent in swellability in water and a method for simply producing the same. A method for producing the swellable crosslinked hyaluronan powder is characterized by comprising mixing a crosslinking agent with a hyaluronan powder in a state dispersed in a liquid medium containing a monovalent alcohol having 1 to 4 carbon atoms and a solubility of the hyaluronan powder of less than 0.1 g/L to cause a crosslinking reaction. Also, the swellable crosslinked hyaluronan powder produced by the method has a swelling ratio in water of 500% or more.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: April 8, 2014
    Assignee: Shiseido Company, Ltd.
    Inventor: Tetsunori Matsumoto
  • Patent number: 8664196
    Abstract: The present invention provides a shark-like chondroitin sulphate and a process for the preparation thereof. In particular, the present invention relates to a shark-like chondroitin sulphate, having a very low amount of 4-sulphate, a high charge density and a biological activity comparable to natural chondroitin sulphates. The invention also relates to a process for the preparation of said shark-like chondroitin sulphate affording substantially higher productivities and better reproducibility of product quality. The shark-like chondroitin sulphate of the invention shows a high molecular mass and its in vitro biological and anti-inflammatory effectiveness has been shown to be comparable to that of natural products making this polysaccharide potentially useful as a drug in pharmaceutical preparations and nutraceuticals.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: March 4, 2014
    Assignee: Gnosis S.p.A.
    Inventors: Ermanno Valoti, Niccolò Miraglia, Davide Bianchi, Marco Valetti, Paola Bazza
  • Publication number: 20140045207
    Abstract: Provided are modified cycloalkyne compounds; and methods of use of such compounds in modifying biomolecules. Embodiments include a cycloaddition reaction that can be carried out under physiological conditions. The cycloaddition reaction involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo and in vitro.
    Type: Application
    Filed: August 8, 2013
    Publication date: February 13, 2014
    Applicant: The Regents of the University of California
    Inventors: John C. Jewett, Carolyn R. Bertozzi, Ellen May Sletten, Chelsea G. Gordon
  • Patent number: 8642756
    Abstract: Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: February 4, 2014
    Assignee: Gilead Pharmasset LLC
    Inventors: Bruce Ross, Michael Joseph Sofia, Ganapati Reddy Pamulapati, Suguna Rachakonda, Hai-Ren Zhang, Byoung-Kwon Chun, Peiyuan Wang
  • Patent number: 8629266
    Abstract: Starch-based dextrin adhesive additives and methods of preparation are described. Adhesives containing the additive exhibit antimicrobial properties and increased water solubility. The additive contains at least one sugar unit, at least one polyphenol side chain, and at least one Frechet-type poly(aryl ether)dendron.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: January 14, 2014
    Assignee: Empire Technology Development LLC
    Inventor: Glen Leon Brizius
  • Patent number: 8629265
    Abstract: The invention relates to a method for producing phosphate-bridged nucleoside conjugates. In the method a nucleophile is first dissolved in a non-aqueous solvent and dried, and a cyclosaligenyl phosphate compound is subsequently added to the solution.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: January 14, 2014
    Assignee: Universitaet Hamburg
    Inventors: Chris Meier, Saskia Wolf, Svenja Warnecke
  • Publication number: 20130324464
    Abstract: Disclosed are an aryl glycoside compound as represented by formula I or formular I?, a pharmaceutically acceptable salt thereof, optical isomer thereof or a prodrug thereof. The present invention relates to a method of preparing said aryl glycoside compound and the use thereof The aryl glycoside compound of the present invention has an excellent ability on inhibit SGLT activity, especially SGLT2 activity, and is diabetes-fighting medicine with great potential.
    Type: Application
    Filed: February 17, 2012
    Publication date: December 5, 2013
    Applicants: SHANGHAI CHEMPARTNER CO., LTD, SHANGHAI YINGLI SCIENCE AND TECHNOLOGY CO., LTD
    Inventors: Zusheng Xu, Su Qian
  • Patent number: 8586550
    Abstract: The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: November 19, 2013
    Assignee: Green Cross Corporation
    Inventors: Jinhwa Lee, Jeongmin Kim, Suk Ho Lee, Junwon Lee, Kwang-Seop Song, Eun-Jung Park, Min Ju Kim, Hee Jeong Seo, Sung-Han Lee, Eun Jung Son, Jong Yup Kim, Suk Youn Kang, Younggyu Kong
  • Patent number: 8586729
    Abstract: A method for producing a ?-enriched protected decitabine comprising: a) coupling a protected 2-deoxy-ribofuranose with a protected 5-azacytosine in the presence of a catalyst to form a reaction mixture comprising the protected decitabine of formula I; and b) quenching the reaction mixture of step a) with a base. The ?-enriched protected decitabine so made may be deprotected to produce a decitabine product in a high yield and purity.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: November 19, 2013
    Assignee: Scinopharm Taiwan Ltd.
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Jianbo Yu, Kun Hu, Lijun Mei
  • Patent number: 8575332
    Abstract: The present invention provides long-acting sustained-release formulations of drugs such as proteins or peptides, which are injectable, completely biodegradable and safe, as well as ensuring efficient encapsulation of the drugs such as proteins or peptides without inhibiting their biological activity. It is possible to achieve injectable sustained-release formulations that ensure efficient encapsulation and long-term sustained release of drugs such as proteins or peptides while retaining their biological activity, when a solution containing a drug and a polysaccharide derivative such as hyaluronic acid having a crosslinkable functional group(s) or a salt thereof is dehydrated in microparticulate form starting from a dilute state, where crosslinking proceeds slowly, to reach a concentration which facilitates crosslinking, to thereby cause crosslinking reaction during concentration, so that the drug is encapsulated into the crosslinked polysaccharide to give drug-carrying microparticles.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: November 5, 2013
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Sei Kwang Hahn, Tsuyoshi Shimoboji
  • Patent number: 8569263
    Abstract: A method of producing silane-modified cationized cellulose that has excellent aqueous dispersibility, including: a step (1) of cationizing water-soluble cellulose ether in a presence of alkali in a mixed solvent of a water-compatible organic solvent to obtain slurry comprising cationized cellulose; a step (2) of adding acid to said slurry and neutralizing said alkali; a step (3) of reacting said cationized cellulose obtained after said neutralization with an aminosilane compound and a step (4) of drying the obtained slurry, wherein: drying is conducted in step (4) at 115-160° C. until weight loss on drying is 5% by weight or less, or there is also including a step (5) of adding a water-compatible organic solvent or a mixed solvent of a water-compatible organic solvent and water to the cationized cellulose after the neutralization so that water content in a whole solvent that contacts the cationized cellulose is 10% by mass or less.
    Type: Grant
    Filed: August 22, 2008
    Date of Patent: October 29, 2013
    Assignee: LION Corporation
    Inventors: Youichirou Kohno, Yoko Osako, Atsushi Ito
  • Patent number: 8563702
    Abstract: There are provided composite fibers of alginate and chitosan. Also provided are fiber materials methods of producing composite fibers or films and composite films. In one embodiment there is provided a composite fiber of alginate and chitosan suitable for use in wound management products, wherein chitosan polymer is bonded to alginate polymer along the length of the fiber.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: October 22, 2013
    Assignee: The University of Bolton Education Corporation
    Inventors: Mohsen Miraftab, Gillian Mary Smart
  • Patent number: 8563532
    Abstract: A process for the crosslinking of at least one polymer selected from polysaccharides and derivatives thereof, which is carried out in an aqueous solvent by the action of an effective and non-excessive amount of at least one crosslinking agent, characterized in that it is carried out on a mixture containing at least one low-molecular weight polymer and at least one high-molecular weight polymer. A process for the preparation of an injectable monophase hydrogel of at least one crosslinked polymer selected from polysaccharides and derivatives thereof. Crosslinked polymers and injectable monophase hydrogels respectively obtainable by each of said processes.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: October 22, 2013
    Assignee: Allergan Industrie SAS
    Inventor: Pierre F. Lebreton
  • Patent number: 8552164
    Abstract: The invention relates to a novel method for production of nanofibrillar chitin, sustainable from an industrial manufacturing standpoint and suitable for producing chitin nanofibrils having improved properties and free from less crystalline components. The invention also relates to novel chitin nanofibrils obtained with said method and characterized by an increased dispersibility in aqueous media. The invention further relates to uses of nanofibrils in pastes and aqueous gels useful for topical on-skin application, to the manufacturing of materials of biomedical interest, as well as to the deposition of chitin nanofibrils on coating surfaces or the incorporation of the same inside of items like, e.g., fibers and fabrics of any Origin, natural as well as synthetic or mixed ones.
    Type: Grant
    Filed: November 23, 2006
    Date of Patent: October 8, 2013
    Assignee: Mavi Sud S.r.l.
    Inventors: Pierfrancesco Morganti, Corrado Muzzarelli
  • Patent number: 8536317
    Abstract: A process for producing a polysaccharide sponge comprises the steps of (A) freezing a photoreactive polysaccharide solution, and (B) irradiating the frozen photoreactive polysaccharide solution with light to crosslink the photoreactive polysaccharide, thereby obtaining the polysaccharide sponge. The process includes simplified steps requiring no removal of solvent, and has such an advantage that impurities are easily removed therefrom.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: September 17, 2013
    Assignee: Seikagaku Corporation
    Inventor: Tomoya Sato
  • Patent number: 8530450
    Abstract: Disclosed are acid polysaccharides characterized by the concomitant presence of alcohol groups esterified with butyric and formic acids.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: September 10, 2013
    Assignee: Sigea S.R.L.
    Inventors: Marco Bosco, Luca Stucchi, Rita Gianni, Antonia Trevisan
  • Patent number: 8524885
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: September 3, 2013
    Assignees: Prochon Biotech Ltd., Bio-Technology General (Israel) Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Patent number: 8513407
    Abstract: A new method is described for the oversulfation of (epi)K5-N-sulfates to obtain (epi)K5-amine-O-oversulfates at extremely high degree of sulfation and for the transformation of these intermediates into new N-acyl-(epi)K5-amine-O-oversulfates basically free of activity on the coagulation parameters and useful in the cosmetic or pharmaceutical field. Also described are pharmaceutical compositions containing, as one of their active ingredients, an (epi)K5-amine-O-oversulfate.
    Type: Grant
    Filed: May 13, 2008
    Date of Patent: August 20, 2013
    Assignee: GLYCORES 2000 S.r.l.
    Inventors: Pasqua A. Oreste, Giorgio Zoppetti
  • Publication number: 20130171180
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportion, in particular a mixture of enantiomers, and particularly a racemate mixture, as well as to their process of preparation, their use in the peptide synthesis, said peptide and the use of said peptide.
    Type: Application
    Filed: December 22, 2011
    Publication date: July 4, 2013
    Applicant: TFCHEM
    Inventors: Geraldine Deliencourt-Godefroy, Hyacinthe Fillon, Thibaut Martin
  • Patent number: 8445670
    Abstract: A method of synthesizing stereochemically defined iminocyclitol comprises replacing an intraring oxygen in a cyclic sugar by an intraring imine to form an iminocyclitol, wherein said iminocyclitol has a defined stereochemical configuration different from a stereochemical configuration of the cyclic sugar. The invention also provides combinatorial libraries of iminocyclitol compounds, allowing for diverse C1 and N-substitution. In addition, provided are methods of treating viral infections with iminocyclitols compounds.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: May 21, 2013
    Assignee: United Therapeutics Corporation
    Inventors: Robert M. Moriarty, Carmen Mitan, Kenneth R. Phares
  • Patent number: 8420790
    Abstract: The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: April 16, 2013
    Assignee: Reliable Biopharmaceutical Corporation
    Inventors: Payal Parth Patel, Chun Ma, Kevin K. Ohrr, Sourena Nadji
  • Patent number: 8410076
    Abstract: A cationized hyaluronic acid and/or a salt thereof includes a quaternary ammonium group-containing group, and has a degree of cationization of 0.15 to 0.6.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: April 2, 2013
    Assignee: Q.P. Corporation
    Inventors: Kazunori Asaoka, Shunichi Fujikawa, Tomoyuki Kanemitsu, Wakako Sakamoto
  • Patent number: 8399656
    Abstract: Glycopeptide having at least one asparagine-linked oligosaccharide at a desired position of the peptide chain obtained by: (1) esterifying hydroxyl of a resin and carboxyl of an amino acid having amino group nitrogen protected with a fat-soluble protective group (AGFPG), (2) removing the protective group to form a free amino group, (3) amidating the free amino group and carboxyl of an amino acid having AGFPG, (4) removing the protective group, (5) repeating the steps (3) and (4), (6) amidating the free amino group and carboxyl of the asparagine portion of an asparagine-linked oligosaccharide having AGFPG, (7) removing the protective group, (8) amidating the free amino group and carboxyl of an amino acid having AGFPG, (9) repeating steps (7) and (8), (10) removing the protective group, and (11) cutting off the resin with an acid; glycopeptide obtained by transferring sialic acid or a derivative thereof to the above glycopeptide.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: March 19, 2013
    Assignees: Otsuka Chemical Co., Ltd.
    Inventor: Yasuhiro Kajihara